AR108411A2 - HEPATITIS C VIRUS INHIBITORS - Google Patents

HEPATITIS C VIRUS INHIBITORS

Info

Publication number
AR108411A2
AR108411A2 ARP170101215A ARP170101215A AR108411A2 AR 108411 A2 AR108411 A2 AR 108411A2 AR P170101215 A ARP170101215 A AR P170101215A AR P170101215 A ARP170101215 A AR P170101215A AR 108411 A2 AR108411 A2 AR 108411A2
Authority
AR
Argentina
Prior art keywords
imidazol
pyrrolidinyl
biphenylyl
methyl
methyl carbamate
Prior art date
Application number
ARP170101215A
Other languages
Spanish (es)
Inventor
Lawrence G Hamann
Gan Wang
David R Langley
Fukang Yang
Laurent Denis R St
Lawrence B Snyder
Edward H Ruediger
Jeffrey Lee Romine
Van N Nguyen
Nicholas A Meanwell
Alain Martel
Omar D Lopez
Rico Lavoie
Clint A James
Jason Goodrich
Andrew C Good
Daniel H Deon
Makonen Belema
Carol Bachand
Original Assignee
Bristol Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland
Publication of AR108411A2 publication Critical patent/AR108411A2/en

Links

Abstract

Reivindicación 1: Un compuesto, caracterizado porque se selecciona de: ((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; (1R,1’R)-2,2’-(4,4’-bifenildiilbis(1H-imidazol-5,2-diil(2S)-2,1-pirrolidindiil))bis(N,N-dimetil-2-oxo-1-feniletanamina); ((1S)-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)-1-metil-2-oxoetil)carbamato de metilo; ((1S)-1-(((2S)-2-(4-(4’-(2-((2S)-4,4-difluoro-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-4-il)-4-bifenilil)-1H-imidazol-2-il)-4,4-difluoro-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; ((1S)-1-(((1R,3R,5R)-3-(5-(4’-(2-((1R,3R,5R)-2-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-azabiciclo[3.1.0]hex-3-il)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-2-azabiciclo[3.1.0]hex-2-il)carbonil)-2-metilpropil)carbamato de metilo; ((1R)-2-oxo-1-fenil-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-tetrahidro-2-furanilcarbonil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)etil)carbamato de metilo; ((1S)-2-metil-1-(((2S)-2-(5-(4’-(2-((2S)-1-(N-2-pirimidinil-D-valil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)propil)carbamato de metilo; ((1R)-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-2-(dimetilamino)-2-fenilacetil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)-2-oxo-1-feniletil)carbamato de metilo; (4,4’-bifenildiilbis(1H-imidazol-5,2-diil(2S)-2,1-pirrolidindiil((1R)-2-oxo-1-fenil-2,1-etandiil)))biscarbamato de dimetilo; (1R)-N,N-dimetil-2-oxo-1-fenil-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-tetrahidro-2-furanilcarbonil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)etanamina; ((1S)-2-((2S)-2-(5-(4’-(2-((2S)-1-(N-(metoxicarbonil)-L-alanil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)-1-metil-2-oxoetil)carbamato de metilo; y ((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3,3-dimetilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2,2-dimetilpropil)carbamato de metilo.Claim 1: A compound, characterized in that it is selected from: ((1S) -1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2S) -2 - ((methoxycarbonyl) amino) -3-methylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) -2- methylpropyl) methyl carbamate; (1R, 1'R) -2,2 '- (4,4'-biphenyldiylbis (1H-imidazol-5,2-diyl (2S) -2,1-pyrrolidindiyl)) bis (N, N-dimethyl-2 -oxo-1-phenylethanamine); ((1S) -2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -2- (diethylamino) -2-phenylacetyl) -2-pyrrolidinyl ) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) -1-methyl-2-oxoethyl) methyl carbamate; ((1S) -1 - (((2S) -2- (4- (4 '- (2 - ((2S) -4,4-difluoro-1 - ((2S) -2 - ((methoxycarbonyl) amino ) -3-methylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-4-yl) -4-biphenylyl) -1H-imidazol-2-yl) -4,4-difluoro-1-pyrrolidinyl) carbonyl) -2- methylpropyl) methyl carbamate; ((1S) -1 - (((1R, 3R, 5R) -3- (5- (4 '- (2 - ((1R, 3R, 5R) -2 - ((2S) -2 - ((methoxycarbonyl ) amino) -3-methylbutanoyl) -2-azabicyclo [3.1.0] hex-3-yl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -2-azabicyclo [3.1.0] hex-2-yl) carbonyl) -2-methylpropyl) methyl carbamate; ((1R) -2-oxo-1-phenyl-2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -tetrahydro-2-furanylcarbonyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) ethyl) methyl carbamate; ((1S) -2-methyl-1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1- (N-2-pyrimidinyl-D-valil) -2- pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) propyl) methyl carbamate; ((1R) -2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -2- (dimethylamino) -2-phenylacetyl) -2-pyrrolidinyl ) Methyl -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) -2-oxo-1-phenylethyl) methyl carbamate; (4,4'-biphenyldiylbis (1H-imidazol-5,2-diyl (2S) -2,1-pyrrolidindiyl ((1R) -2-oxo-1-phenyl-2,1-ethanediyl))) dimethyl biscarbamate ; (1R) -N, N-dimethyl-2-oxo-1-phenyl-2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -tetrahydro -2-furanylcarbonyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) ethanamine; ((1S) -2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1- (N- (methoxycarbonyl) -L-alanyl) -2-pyrrolidinyl) -1H- methyl imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) -1-methyl-2-oxoethyl) carbamate; and ((1S) -1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2S) -2 - ((methoxycarbonyl) amino) -3.3 -dimethylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) -2,2-dimethylpropyl) methyl carbamate.

ARP170101215A 2006-08-11 2017-05-09 HEPATITIS C VIRUS INHIBITORS AR108411A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83699606P 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
AR108411A2 true AR108411A2 (en) 2018-08-15

Family

ID=41175598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101215A AR108411A2 (en) 2006-08-11 2017-05-09 HEPATITIS C VIRUS INHIBITORS

Country Status (3)

Country Link
CN (1) CN101558059B (en)
AR (1) AR108411A2 (en)
TW (1) TWI400072B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281910A1 (en) * 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TW201200522A (en) * 2010-03-24 2012-01-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
US8921372B2 (en) * 2010-11-04 2014-12-30 Theravance Biopharma R&D Ip, Llc Inhibitors of hepatitis C virus
MX366318B (en) * 2010-11-19 2019-07-05 Ligand Pharm Inc Heterocycle amines and uses thereof.
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) * 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013067267A1 (en) * 2011-11-03 2013-05-10 Theravance, Inc. Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine
CN103304551B (en) * 2012-03-14 2017-06-13 北京凯因科技股份有限公司 Hepatitis AG14361
US20160158200A1 (en) * 2013-07-09 2016-06-09 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
CN106279121B (en) * 2014-01-21 2019-05-24 杭州普晒医药科技有限公司 The salt and crystal form or amorphous article, preparation method, pharmaceutical composition and purposes containing them of a kind of compound
CN108084172A (en) * 2014-02-21 2018-05-29 常州寅盛药业有限公司 Anti- hepatitis C virus compound
WO2015184644A1 (en) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 Compounds and pharmaceutical compositions for inhibiting hepatitis c virus, and uses thereof
CN105524049B (en) * 2014-09-28 2018-11-06 正大天晴药业集团股份有限公司 Deuterated hepatitis C virus NS 5 A protein on NS inhibitor
CN104546780A (en) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 Daclatasvir film coating tablet preparation and preparation method thereof
WO2017076358A1 (en) * 2015-11-06 2017-05-11 苏州晶云药物科技有限公司 New crystal form of imidazolyl biphenyl compound salt and preparation method thereof
CN106496199A (en) * 2016-10-19 2017-03-15 上海博志研新药物技术有限公司 His Wei of Dacca and its preparation method of intermediate
CN110382487B (en) * 2017-03-22 2021-04-02 正大天晴药业集团股份有限公司 Silicon-containing compounds for use against hepatitis c virus infection
CN115448892B (en) * 2022-09-19 2023-07-07 郑州铁路职业技术学院 Synthesis method of benzothiadiazole heterocyclic compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249977A1 (en) * 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections

Also Published As

Publication number Publication date
TW200934486A (en) 2009-08-16
CN101558059A (en) 2009-10-14
TWI400072B (en) 2013-07-01
CN101558059B (en) 2014-12-03

Similar Documents

Publication Publication Date Title
AR108411A2 (en) HEPATITIS C VIRUS INHIBITORS
EA201000300A1 (en) METHOD FOR SYNTHESIS OF COMPOUNDS SUITABLE FOR THE TREATMENT OF HEPATITIS C
HK1144089A1 (en) Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2- ((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5- yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2- methylpropyl)carbamate dihydrochloride salt
NZ594981A (en) Hepatitis c virus inhibitors
HRP20120440T1 (en) Hepatitis c virus inhibitors
PE20160800A1 (en) METHYL ((1S)-1-(((2S)-2-(5-(4-(2-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL COMBINATION )-1H-IMIDAZOL-5-IL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-IL-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE (DACLATASVIR) AND N-(TERT-BUTOXICARBONYL)-3- METHYL-L-VALYL-(4R)-4-((7-CHLORO-4-METHOXY-1-ISOQUINOLINYL)OXYN-((1R,2S)-1-((CYCLOPROPYLSULFONYL)CARBAMOIL)-2-VINYLCYCLOPROPYL) -L-PROLINAMIDE (ASUNAPREVIR).
HRP20120706T1 (en) Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
NZ595168A (en) Hepatitis c virus inhibitors
NZ605440A (en) Solid compositions comprising an hcv inhibitor
NZ594068A (en) Substituted benzimidazole compounds as hepatitis c virus inhibitors
JP2013510857A5 (en)
PE20121354A1 (en) HEPATITIS C VIRUS INHIBITORS
HRP20160410T1 (en) Hepatitis c virus inhibitors
JP2011530531A5 (en)
PE20140038A1 (en) ANTIVIRAL COMPOUNDS
JP2012518000A5 (en)
JP2012522056A5 (en)
JP2010500415A5 (en)
JP2010500414A5 (en)
EA200400183A1 (en) CRYSTALS CONTAINING SALT N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-Fluoro-2-OXO-1,2-DIHYDRO-3H-INDOL-3-ILIDEN) METHYL] -2,4-DIMETHYL- 1H-PIRROL-3-CARBOXAMIDE WITH APPLE ACID, METHODS FOR THEIR PRODUCTION AND THEIR COMPOSITION
PE20120533A1 (en) HEPATITIS C VIRUS INHIBITORS
RU2008112683A (en) FAP INHIBITORS
JP2012522053A5 (en)
PE20061373A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 'N- (2-CHLORO-6-METHYLPHENIL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERAZINYL] -2-METHYL-4-PYRIMIDINYL] AMINO] -5- THIAZOLCARBOXAMIDE
KR910006224A (en) Amino acid derivatives

Legal Events

Date Code Title Description
FB Suspension of granting procedure